Baby formula imports are reportedly expected to face tariffs again in 2023. A White House spokesman said the tariff waivers doubled the number of manufacturers selling baby formula in the United States. (The Wall Street Journal)
The Biden administration said starting January 5, the U.S. will require negative COVID-19 tests for travelers from China. The U.S. will require airline passengers coming from China to show negative COVID-19 tests as global concerns ratchet higher over the virus’s spread since the country lifted its restrictions. (Bloomberg)
The XBB COVID variant is now dominant in the Northeast, according to data from the Centers for Disease Control and Prevention. The Omicron subvariant XBB accounts for about 52.6% of all cases in New England between Dec. 18 and Dec. 24, according to the CDC. XBB constitutes 18.3% of cases across the country. (MassLive)
Public health experts have once again reminded people – especially the elderly – to get a COVID-19 booster shot this year, despite the low uptake and widespread vaccine fatigue. Only about 15% of people who are eligible to get the shot have received it. (NPR)
Sanofi, GSK and BioNTech are three biotech stocks that traders should have in their portfolio in 2023, experts said. While the broader market is grappling with rising interest rates and inflation, innovation — the sector’s driving force — continues to take place, with the trend expected to continue in 2023. M&A in the drug and biotech sector is also expected to pick up noticeably. (Yahoo! Finance)
